trial · primary record
durvalumab
Hepatocellular Cancer
| Phase | Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 27 |
| Primary completion | 2027-12-31 |
| Primary endpoint | To evaluate the 6-month progression free survival (PFS) in participants with advanced HCC BCLC stage B treated with bevacizumab, durvalumab, tremelimumab and TACE |
| Registry ID | NCT03937830 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:33:02.511Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT03937830
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.